Aleksandr Lazaryan, MD, MPH, PhD

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Aleksandr Lazaryan

Contact Info

Mailing Address:
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Kristin Blomquist

Administrative Phone
612-625-8942

Administrative Email
krblomqu@umn.edu

Administrative Fax Number
612-625-6919

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation


Hematologist / Oncologist


Medical School, Yerevan State Medical University, Yerevan, Armenia

Internal Medicine Residency, Cleveland Clinic Foundation, Cleveland, OH

Hematology and Medical Oncology Fellowship, Cleveland Clinic, Cleveland, OH

Summary

Dr. Lazaryan received his medical degree from the Yerevan State Medical University, Yerevan, Armenia. He completed residency training in internal medicine and fellowship training in hematology and medical oncology at the Cleveland Clinic Foundation before joining the faculty at the University of Minnesota in 2012.

Awards & Recognition

  • Chronic Graft-versus-Host Diesase Consortium Award (2012)
  • Certificate of Recognition of Dedicated Service, Cleveland Clinic (2011)
  • Delta Omega Honorary Award in Public Health (2001)
  • American Society of Hematology Abstract Achievement Award (2011)
  • Recipient of an NIH grant from the Chronic GVHD Consortium (U54CA163438) which is a part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR) and National Center for Advancing Translational Sciences (NCATS)

Professional Associations

  • Member, American Society for Blood and Marrow Transplantation (2011-present)
  • Golden Key International Honor Society (2008-present)
  • Member, American Society of Clinical Oncology (2008-present)
  • Member, American Society of Hematology (2010-present)
  • Global and site-specific Principal Investigator (PI) on a number of national and international studies in BMT and hematological malignancies, including those sponsored by the Center for International Blood Marrow Transplant Research (CIBMTR), pharmaceutical industry, and the National Institutes of Health (NIH)
  • Expert member of multiple intra- and extramural committees such as the Lymphoma/Myeloma and GV

Research

Publications

  • Lazaryan A, Weisdorf D, Defor T, Brunstein C, MacMillan M, Bejanyan N, Holtan S, Blazar B, Wagner J, and Arora M. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched related donors. Biol Blood Marrow Transplant. 2015 Sep 10. pii: S1083-8791(15)00613-8.
  • Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim H, Matas A, and Issa N. Outcomes of Kidney Retransplantation in Recipients with Prior Post-Transplant Lymphoproliferative Disorder Clinical Transplantation Oct 2015
  • Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):926-33
  • Khera N, Chai X, Duong H, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Flowers M, Cutler C, Lukez A, Arai S, Lazaryan A, Jagasia M, Pusic I, Wood W, Lee S, Pidala J. Prospective Longitudinal Study of Late Acute Graft Versus Host Disease after Hematopoietic Cell Transplantation: A Report from Chronic GVHD Consortium. Biol Blood Marrow Transplant. Vol 21, Issue 2, Supplement, Pages S336–S337
  • Omer A, Weisdorf D, Lazaryan A, Shanley R, Blazar B, MacMillan M, Brunstein C, Bejanyan N, Arora M. Late Onset Acute GVHD (late aGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT). Biol Blood Marrow Transplant. Vol 21, Issue 2, S341–S342
  • Wood W, Stephanie J. Lee S, Chai X, Flowers M, Cutler C, Inamoto Y, Lazaryan A, Pidala J, Palmer J, Martin P. Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease Biol Blood Marrow Transplant. Vol 21, Issue 2, S352–S353
  • Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris M, Ustun C, Lazaryan A, McClune B, Warlick E, Kantarjian H, Weisdorf D, Miller J, Vallera D Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15;21(6):1267-72
  • Lazaryan A, Weisdorf D, Defor T, Brunstein C, MacMillan M, Bejanyan N, Holtan S, Blazar B, Wagner J, and Arora M. Risk Factors for Acute and Chronic Gvhd after Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Relative Risks with Umbilical Cord Blood (UCB) and Matched Related Donors (MRD). Blood: 124 (21) 2015 (Oral presentation at ASH Annual Meeting)
  • Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K,Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R. Mature results of MM-011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. Am J Hematol. 2014 Apr;89(4):349-54
  • Wilke C, Yuan J, Cao Q, Lazaryan A, Lee C, Dusenbery K Role of Consolidative Radiation Therapy Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Int J of Radiation Oncology 2014 Vol 90, Issue 1, S674
  • Holtan S, DeFor T, Lazaryan A, Bejanyan N, Arora M, Blazar B, MacMillan M, Weisdorf D. What Predicts Success for a New Composite Endpoint: Graft–versus-Host Disease-Free and Relapse-Free Survival (GRFS) after Allogeneic Hematopoietic Cell Transplantation Blood 2015 125:1333-1338
  • Lazaryan A, Wang T, Spellman S, Wang H, Müller C, Fernandez-Viña M, Verneris M, Arora M, Weisdorf D, Horowitz M, Lee S Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study. 2014 American Society of Hematology Blood: 124 (21)
  • Bachanova V, Cao Q, Ustun C, Kendi AT, Froelich J, Lazaryan A, and Burns LJ. Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT. Bone Marrow Transplant. 2015 Jan;50(1):142-4
  • Lazaryan A, Wagner J, Brunstein C, Defor T, MacMillan M, Blazar B, Weisdorf D, Arora M.High-Resolution Donor-Recipient HLA Matching Does Not Influence Acute or Chronic Gvhd in Umbilical Cord Blood Transplantation Biol Blood Marrow Transplant Vol 20, Issue 2,S140, 2014

Clinical

Specialties

  • Blood and Marrow Transplant Surgery
  • Cancer
  • Hematology/Oncology

Board Certifications

  • American Board of Internal Medicine
  • Hematology
  • Medical Oncology

Clinical Interests

Lymphoma (Non-Hodgkin and Hodgkin); Blood and Marrow Transplantation; Graft-versus-Host Disease; Post-Transplant Lymphoproliferative Disorder (PTLD); Leukemia